Merck Millipore Announces Agreement with Precision Biologics
News Feb 05, 2015
Merck Millipore has announced an agreement for providing upstream process development services for Precision Biologics, Inc., a Texas-based clinical-stage biotechnology company, to advance a preclinical monoclonal antibody.
The antibody, NEO-201, binds to a tumor-specific antigen found in several forms of cancer, offering therapeutic potential across multiple cancer types, including colorectal, lung, ovarian, and pancreatic, an especially deadly cancer with limited treatment options.
Under the agreement, Merck Millipore will provide process development through its Provantage® Services offering, which leverages the company’s deep expertise in biopharmaceutical manufacturing to help customers design and develop custom processes that improve yield and productivity while reducing costs and accelerating time to market. The process development will occur at Merck Millipore’s single-use GMP biodevelopment center in Martillac, France.
“We chose to partner with Merck Millipore because of their legacy of scientific and process development expertise,” said Philip M. Arlen, M.D., President and Chief Executive Officer of Precision Biologics, Inc. “In addition to their experience in the development of processes for manufacturing monoclonal antibodies, their approach to the structure of our partnership was very appealing and well-suited to an emerging company like ours. We are confident that Merck Millipore will be a valuable partner in advancing NEO-201 and helping to bring a potential new therapeutic to patients in need.”
“We are delighted to partner with Precision Biologics, Inc. to support the process development for NEO-201 and its anticipated progression into clinical trials,” said Udit Batra, President and Chief Executive Officer of Merck Millipore.
Batra continued, “Our Provantage® team is committed to developing an efficient, effective and robust manufacturing process to help reduce the time and cost required to advance this important pre-clinical drug candidate into the next phase for clinical production.”
Macrophage's Role in Maintaining Tattoos Could Hold Key to RemovalNews
Researchers have discovered that, though a tattoo may be forever, the skin cells that carry the tattoo pigment are not. Instead, the cells can pass on the pigment to new cells when they die. The study suggests ways to improve the ability of laser surgery to remove unwanted tattoos.READ MORE
New Causes of Cellular Decline in Prematurely Aging Kids DiscoveredNews
In a recent paper published in Cell Reports, Saint Louis University researchers have uncovered new answers about why cells rapidly age in children with a rare and fatal disease. The data points to cellular replication stress and a mistaken innate immune response as culprits, and the team found success in the laboratory in blocking these processes with vitamin D.READ MORE
Measuring Neutrophil Motility Could Lead to Accurate Sepsis DiagnosisNews
Mass. General researchers design device that rapidly diagnoses sepsis with more than 95 percent accuracy.READ MORE